Sanofi SA ((SNY)), Sanofi ((SNYNF)), Sanofi ((DE:SNW)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Sanofi SA is conducting a prospective, non-interventional, multinational observational study titled ‘A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)’. The study aims to evaluate the effectiveness and safety of isatuximab in routine clinical practice for patients with RRMM, focusing on overall response rate, progression-free survival, and quality of life.
The study involves the administration of isatuximab, a drug delivered intravenously, alongside other treatments like Pomalidomide, Dexamethasone, and Carfilzomib. These interventions target patients with multiple myeloma who meet specific criteria.
This observational study follows a cohort model with a prospective time perspective, aiming to gather data over a 2.5-year duration per participant. It does not involve random allocation or masking, as it seeks to observe real-world outcomes.
The study began on August 13, 2020, with an estimated completion date set for June 24, 2025. These timelines are crucial for tracking progress and anticipating results that could influence treatment approaches.
Sanofi’s ongoing study could significantly impact its stock performance and investor sentiment, particularly if results demonstrate substantial benefits of isatuximab, potentially positioning the company favorably against competitors in the oncology sector.
The study is currently active but not recruiting, with further updates available on the ClinicalTrials portal.